The Q1 2024 sales announcement took place on 24 April 2024 at 7am CET/1am EST.
24 April 2024 – 1 mins read
PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
Investor and analyst conference call
An investor and analyst conference call, complete with presentation and a subsequent interactive Q&A session took place on 24 April 2024 at 1:00 PM CET.
Q1 2024 sales presentation & highlights
The presentation will be shared on 24 April 2024, prior to the investor and analyst conference call.
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.
Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).
Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.
If you are experiencing difficulties registering for the investor and analyst conference call, please contact: nicolas.bogler@ipsen.com
Craig Marks
Vice President, Investor Relations
Nicolas Bogler
Senior Manager, Investor Relations
